C
Cantos
Venture CapitalActiveA pre-seed firm obsessively pursuing the near frontier вАУ where software, hardware, & wetware intersect.
53
Investments
0
Exits
—
AUM
0.0%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Cantos.
Investment Thesis & Strategy
Cantos invests in pre-seed companies at the intersection of software, hardware, and wetware, seeking to fund innovative ventures at the near frontier.
Investment Activity
Deals per year over the last 3 years
3
20212
20225
2023Portfolio Companies
Selected investments from their portfolio of 53 companies
T
Third Rock Ventures
Biotech · Growth, 2023
D
Deepcell
Biotech · Series B, 2023
I
Interline Therapeutics
Biotech · Series A, 2023
M
Moonwalk Therapeutics
Biotech · Series A, 2023
A
Arc Institute
Biotech · Growth, 2023
B
Boundless Bio
Biotech · Series A, 2022
S
Seismic Therapeutic
Biotech · Series B, 2022
T
Tessera Therapeutics
Biotech · Growth, 2021
N
Nference
AI/ML · Growth, 2021
G
Generate Biomedicines
Biotech · Series B, 2021
Frequently Asked Questions
Cantos focuses on Series A, Series B, Series C+ stage investments.
Related Investors
Index Ventures
San Francisco, United States · 827 deals
First Round Capital
San Francisco, United States · 742 deals
Benchmark
San Francisco, United States · 600 deals
Founders Fund
San Francisco, United States · 564 deals
Matrix Partners
San Francisco, United States · 549 deals
Bain Capital Ventures
San Francisco, United States · 438 deals